Lenalidomide and Low-dose Cyclophosphamide for MALT Lymphoma
Status:
Not yet recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
Considering that lenalidomide and cyclophosphamide are found to have anti-tumor effects in
MALT lymphoma, the investigators speculated that combined lenalidomide and low-dose
cyclophosphamide can increase the overall response rate as well as dural time of tumor
remission, and avoid alternative treatments, including radiotherapy or chemotherapy-related
adverse effects in antibiotics-unresponsive, relapsed or refractory extranodal MALT lymphoma.
Therefore, in this proposal, the investigators will design a prospective phase II study to
evaluate the treatment efficacies of combination of oral lenalidomide and low-dose
cyclophosphamide (LC: lenalidomide [Leavdo®] 15 mg daily, day 1 to day 21; cyclophosphamide
[Endoxan] 50 mg daily, day 1 to day 21; courses will be repeated every 28 days) in patients
with antibiotics-unresponsive, relapsed or refractory extranodal MALT lymphoma.